Remidio & RetinaRisk to Boost AI-Driven Diabetic Retinopathy Screening in India & Iceland

The collaboration aims to deliver scalable, personalized, and cost-effective DR screening models to address the growing burden of diabetes-related vision loss.

Bengaluru-based Remidio Innovative Solutions, a global leader in AI-powered ophthalmic diagnostics, has partnered strategically with Iceland-based health tech company RetinaRisk to enhance diabetic retinopathy (DR) screening in India and Iceland.

The collaboration aims to deliver scalable, personalized, and cost-effective DR screening models to address the growing burden of diabetes-related vision loss.

The partnership integrates two advanced technologies: Remidio’s Medios DR AI, a smartphone-based edge AI solution for real-time DR detection, and RetinaRisk’s personalized risk triaging algorithm, which predicts progression to sight-threatening DR.

Medios DR operates entirely offline, enabling on-the-spot DR grading without internet access. RetinaRisk complements this by calculating individual risk levels using key clinical inputs like HbA1c, blood pressure, diabetes type and duration, and DR status to recommend tailored screening intervals.

Globally, diabetic retinopathy affects an estimated 22.27% of people with diabetes. This number is projected to rise from 103.12 million in 2020 to 160.50 million by 2045.

More than 9.2 million individuals are affected in India alone, underscoring the urgent need for innovative, scalable screening solutions.

The collaboration will launch pilot programs in high-prevalence diabetic populations across India.

These pilots aim to establish a scalable framework for prioritized referrals, risk-based screening intervals, and longitudinal tracking—ultimately reducing preventable vision loss from DR.

Stay tuned for more such updates on Digital Health News.